Mannitol Βιοσερ

Mannitol, the active ingredient in Mannitol Βιοσερ, is an osmotic diuretic presented as an intravenous solution for IV use. It is employed to lower intracranial and intraocular pressure, treat cerebral edema, and promote diuresis in acute renal failure.

GNH USA supplies Mannitol Βιοσερ as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mannitol is an osmotic diuretic used in conditions that require rapid reduction of fluid pressure within the central nervous system or the eye. - Intracranial pressure: lowers pressure to prevent brain herniation. - Cerebral edema: reduces swelling and improves neurological outcomes. - Acute renal failure: promotes diuresis to aid renal clearance. - Intraocular pressure: decreases pressure to manage acute glaucoma attacks.

Mannitol may cause a range of adverse reactions, from mild to severe. Monitoring patients for these effects is essential during therapy.

Common Side Effects: - Headache: mild to moderate discomfort often reported during infusion. - Nausea: transient feeling of queasiness. - Electrolyte imbalance: changes such as hyponatremia or hypokalemia. - Thirst: increased desire for fluids.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in the lungs requiring urgent care. - Severe dehydration: excessive fluid loss leading to hypotension. - Anaphylaxis: rare allergic reaction with rash, swelling, and breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm potentially life‑threatening.

Before initiating Mannitol therapy, clinicians should consider several safety measures. - Assess renal function: avoid or adjust use in patients with impaired kidneys. - Monitor electrolytes: watch for hyponatremia, hypokalemia, and other disturbances. - Avoid rapid infusion: administer over the recommended period to reduce cardiovascular stress. - Use with caution in heart failure: risk of fluid overload. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mannitol can interact with other medications, influencing efficacy and safety.

Major Interactions (Avoid): - Loop diuretics: additive diuretic effect may cause severe electrolyte loss. - Insulin: osmotic shifts can enhance hypoglycemia. - Nephrotoxic agents: increased risk of renal impairment.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may potentiate hypotension. - Antihypertensives: additive blood‑pressure lowering effect. - Contrast media: heightened risk of renal dysfunction.